Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Project Oncology®
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Analyzing Key Data from LAG-3 Combinations in the Treatment of Metastatic Melanoma
Analyzing Key Data from LAG-3 Combinations in the Treatment of Metastatic Melanoma
MinuteCE®
Analyzing Key Data from LAG-3 Combinations in the Treatment of Metastatic Melanoma
0.75 program credits
- Hussein Tawbi, MD, PhD
0.75 program credits
Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints
Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints
MinuteCE®
Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints
0.75 program credits
- Hussein Tawbi, MD, PhD
0.75 program credits
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
MinuteCE®
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
0.75 program credits
- Allison Betof Warner, MD, PhD
0.75 program credits
Future Directions: Targeting LAG-3 in Melanoma Treatment
Future Directions: Targeting LAG-3 in Melanoma Treatment
MinuteCE®
Future Directions: Targeting LAG-3 in Melanoma Treatment
0.75 program credits
- Hussein Tawbi, MD, PhD
0.75 program credits
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
MinuteCE®
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
1.00 program credit
- Samuel J. Klempner, MD
1.00 program credit
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
MinuteCE®
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
1.00 program credit
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.00 program credit
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
MinuteCE®
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
1.00 program credit
- Yelena Janjigian, MD
1.00 program credit

Medical News

Medical News
Review Unveils Cell-Based Sepsis Immunotherapies in China
miragenews.com
05/17/2024
Read more
Medical News
New Study Links Protein Secreted by Blood Vessels to Drug-Resistant Cancer
eurekalert.org
05/16/2024
Read more
Medical News
New Nutrition Guidelines Put Less Sugar and Salt on the Menu for School Meals
nytimes.com
05/16/2024
Read more
Medical News
Study Shows Virus That Causes COVID-19 Can Penetrate Blood-Retinal-Barrier and Could Damage Vision
medicalxpress.com
05/15/2024
Read more

See more news

CME/CE

First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
MinuteCE®
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
0.75 program credits
- Allison Betof Warner, MD, PhD
0.75 program credits
Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status
Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status
MinuteCE®
Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status
0.75 program credits
- Hussein Tawbi, MD, PhD
0.75 program credits
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
MinuteCE®
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
1.00 program credit
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.00 program credit
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
CME/CE
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
0.25 credits
- Caitlin Costello, MD
- Sagar Lonial, MD, FACP
0.25 credits

Clinical Practice

Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
MinuteCE®
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
0.75 program credits
- Allison Betof Warner, MD, PhD
0.75 program credits
MinuteCE®
Leveraging LAG-3: Innovative Immunotherapy Combinations for First-Line Metastatic Melanoma Treatment
0.75 credits 7 episodes
- Allison Betof Warner, MD, PhD
- Hussein Tawbi, MD, PhD
0.75 credits 7 episodes
Optimizing CLL Care and Quality of Life with Patient-Centered Strategies
Optimizing CLL Care and Quality of Life with Patient-Centered Strategies
Project Oncology®
Optimizing CLL Care and Quality of Life with Patient-Centered Strategies
- Charles Turck, PharmD, BCPS, BCCCP
- Richard R. Furman, MD
- Javier Pinilla, MD, PhD
Sequencing CLL Therapies: A Guide to First-Line, Second-Line, and Beyond
Sequencing CLL Therapies: A Guide to First-Line, Second-Line, and Beyond
Project Oncology®
Sequencing CLL Therapies: A Guide to First-Line, Second-Line, and Beyond
- Charles Turck, PharmD, BCPS, BCCCP
- Seema A. Bhat, MD
- Joanna Rhodes, MD, MSCE

Programs

B-Cell Lymphoma Care: Overcoming Challenges in the Second-Line Setting
B-Cell Lymphoma Care: Overcoming Challenges in the Second-Line Setting
Project Oncology®
B-Cell Lymphoma Care: Overcoming Challenges in the Second-Line Setting
- Matthew Lunning, DO, FACP
Navigating CLL Treatment: A Deep Dive into Efficacy and Safety
Navigating CLL Treatment: A Deep Dive into Efficacy and Safety
Project Oncology®
Navigating CLL Treatment: A Deep Dive into Efficacy and Safety
- John Russell, MD
- Seema A. Bhat, MD
The CLL Landscape: A Look at Current and Future Therapies
The CLL Landscape: A Look at Current and Future Therapies
Project Oncology®
The CLL Landscape: A Look at Current and Future Therapies
- John Russell, MD
- Andrew H. Lipsky, MD
Personalizing Relapsed/Refractory CLL Care: Key Factors to Consider
Personalizing Relapsed/Refractory CLL Care: Key Factors to Consider
Project Oncology®
Personalizing Relapsed/Refractory CLL Care: Key Factors to Consider
- Charles Turck, PharmD, BCPS, BCCCP
- Lindsey Roeker, MD